**Cross-Border Challenges: The recent cVDPV2 Polio Outbreak in Gaza**

Itamar Grotto1, Hazem Agha2, Ahmad Abu Al-Halaweh3, Nadav Davidovitch1,2, Martin McKee4, Dorit Nitzan1

1 School of Public Health, Ben Gurion University of the Negev, Beer-Sheva, Israel.

2 Association of School of Public Health in the European Region (ASPHER) Public Health Emergencies Task Force

3 Diabetes Palestine

The global effort to eradicate polio faces a complex web of challenges as it enters its final stages. Despite considerable progress, wild virus transmission persists in Afghanistan and Pakistan, both experiencing security issues that limit accessibility in some regions and hinder vaccination efforts. There and elsewhere, vaccination programmes face high levels of hesitancy fuelled by conspiracy theories that thrive on distrust.

Compounding this problem is the emergence of circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in previously polio-free areas, including in Israel and Gaza.1 The current conflicts in this region have produced a humanitarian crisis in several countries, with displacement of more than 1.9 million people in Gaza, 250,000 people in Israel, and 1.2 million in Lebanon. The situation in Gaza is especially severe, with reduced access to essential health services, including life-saving care and vaccines, including the polio vaccine. These problems are compounded by a lack of clean water, food, and electricity, which exacerbates public health risks, including outbreaks of communicable and waterborne diseases. As a result, polio vaccination coverage in the region has fallen.1,2

**Global Epidemiology of cVDPV2**

Unvaccinated groups in regions with poor water, sanitation, and hygiene conditions, fragile health systems, and, especially, those experiencing wars and conflicts are at increased risk for circulating vaccine-derived poliovirus (cVDPV). In recent years, cVDPV2 has become a major global public health concern, particularly among populations with low vaccination coverage.

The global success in eradicating wild poliovirus type 2 (WPV2) in 1999 led to the cessation of the type 2 component of the oral polio vaccine (OPV) in 2016. However, the continued circulation of cVDPV in countries with inadequate vaccination coverage of the enhanced potency inactivated poliovirus vaccine (eIPV) enables the attenuated vaccine-derived virus to circulate and further mutate, increasing the risk of cVDPV2 outbreaks. As of 2024, cVDPV1 has been reported in 22 countries, while cVDPV2 has been reported in 15 countries in multiple regions. Africa is the worst affected due to poor vaccination coverage, wars and conflicts, displacement, poor water, sanitation, and hygiene, and barriers to accessing healthcare.15

In the World Health Organization (WHO) Eastern Mediterranean region, cVDPV2 has been detected in Afghanistan and Pakistan, where wild poliovirus type 1 (WPV1 remains endemic, complicating eradication efforts. Additionally, cVDPV2 has been detected in environmental samples in countries such as Iran and Somalia, indicating ongoing transmission, including importation from other countries, and highlighting the need for continued vigilance.16 The WHO Western Pacific region has also reported cases of cVDPV2, particularly in Indonesia, where outbreaks in recent years have prompted emergency vaccination campaigns. In Asia, Tajikistan has experienced outbreaks linked to cVDPV2 strains originating in Pakistan, illustrating the potential of this virus for cross-border spread.16

The resurgence of cVDPV2 emphasises the need for sustained vaccination efforts, particularly in high-risk regions. The introduction of the novel oral polio vaccine type 2 (nOPV2), designed to be more genetically stable and less likely to revert to virulence than previous vaccine types, represents a critical tool in combating these outbreaks.16 However, the ongoing challenge of ensuring high vaccination coverage, especially in conflict-affected and underserved areas, remains a major barrier to global polio eradication efforts.17

Thanks to global vaccination efforts, the number of polio cases originating from wild poliovirus has fallen from hundreds of thousands annually in the 1980s to 27 cases globally today. As of October 2024, 14 cases of WPV1 were reported in Afghanistan and 13 cases in Pakistan.18 The world is close to making polio the second human disease to be eradicated. However, this “polio endgame” phase exposes the world to the challenges of the residuals of the cVDPVs. Therefore, there is a need to ensure that all children are immunised against all strains of the virus using eIPV 1,2,3, combined with simultaneous administration of bivalent oral polio vaccine (bOPV) 1,3 in areas with poor sanitation and hygiene. In cases of cVDPV2 outbreaks, nOPV2 is recommended as the first-line vaccine, used in conjunction with eIPV, aiming to rapidly and widely stop the circulation of the virus. Regional polio vaccination strategies should be tailored to address a whole-of-community approach that prevents the spread of polio, as borders do not confine hazards or microorganisms. The current polio situation in Israel and Gaza is a clear illustration of this need.

**Polio in Israel and Gaza**

In 1977 and 1978, Gaza experienced a severe polio outbreak, with more than 70 cases occurring each year, even among partially vaccinated children. Simultaneous outbreaks of enteric diseases and measles exacerbated this crisis. In a remarkable display of collaboration, Israeli and Palestinian health officials, WHO, and the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA) took decisive action. They implemented a new polio control strategy based on advice from a WHO consultant, Dr. Joseph Melnick, which involved combining the OPV with two doses of inactivated polio vaccine (IPV). This strategic approach coined as the “Gaza system,” received full support from the Israeli Civil Administration, responsible for overseeing the healthcare system in Gaza and the West Bank, marking an important milestone in the fight against polio.2 Following this success, the “Gaza system” was adopted by other countries in the Mediterranean region.

Figure 1 illustrates the polio vaccination timeline in Israel and Gaza since 1988, along with key polio-related events up to the recent cVDPV2 outbreak in Gaza.

In 1988, Israel experienced a major poliomyelitis outbreak, marking the most extensive occurrence of paralytic poliomyelitis in the country since 1979. This outbreak, caused by WPV1, resulted in 15 confirmed cases of paralytic poliomyelitis between July and October of that same year. The outbreak also saw the co-identification of a clinical case in the West Bank, alongside the detection of WPV1 in sewage samples from Gaza. Most cases (12 of the 15) were concentrated in Israel’s Hadera subdistrict, an area where, since 1982, eIPV had been exclusively used for infant vaccination.5 In response to the outbreak, the Israeli Ministry of Health launched a mass vaccination campaign, targeting all individuals under 40 years old for vaccination with OPV, which led to the elimination of the virus. The outbreak precipitated the implementation of the combined eIPV and OPV vaccination schedule in Israel.6

Following the 1988 outbreak, a collaborative early warning system was established. This included the routine monitoring of sewage from Israel, the West Bank, and Gaza at the Central Virus Laboratory of Israel’s Ministry of Health.7

WHO declared Israel, and subsequently the West Bank and Gaza, polio-free in 2002 and 2010, respectively.7,8 In 2004, Israel discontinued the use of OPV in line with the WHO European Region, which had declared the region polio-free the previous year (while Israel is in WHO’s European Region, Palestine is in the Eastern Mediterranean Region). However, Gaza has continued to employ the Melnick plan.

In May 2013, a silent outbreak of WPV1 in southern Israel was identified via sewage monitoring.9 The same virus had previously been detected in sewage samples in Cairo, Egypt. Genetic analyses linked it to strains circulating in Pakistan, indicating its spread from South Asia to the Middle East.10 Later in 2013, the virus spread silently across Israel, as evidenced by environmental surveillance results but with no clinical cases.11 The outbreak extended further, with WPV1 identified in sewage samples from both the West Bank and Gaza.12 In response to the widespread detection of WPV1, authorities in Israel, in collaboration with their counterparts in the Palestinian territories, initiated a coordinated public health response that included a mass vaccination campaign using bOPV. Moreover, due to the ongoing threat posed by the virus, Israel made the strategic decision to re-include bOPV in its national vaccination schedule, a move aimed at ensuring sustained immunity and preventing future outbreaks.13 The epidemiological rationale was that without the deployment of the OPV, it is doubtful that the polio outbreak could have been effectively contained and, in due course, eradicated.14

**Latest Epidemiology of cVDPV2 in Israel**

In 2022, Israel reported a case of vaccine-associated paralytic poliomyelitis (VAPP) linked to cVDPV2. At the same time, cVDPV2 was detected in environmental samples, specifically in sewage, underscoring the silent circulation of the virus within the population. This was part of a broader pattern observed globally, as during the same period, cVDPV2 was also identified in sewage in the United Kingdom and the United States, highlighting the potential for the re-emergence of this virus even in polio-free regions. The Israeli Ministry of Health responded by intensifying surveillance and reassessing vaccination strategies to increase vaccination coverage with eIPV. The situation underscored the importance of continuous vigilance and adaptability in public health strategies to prevent the re-emergence of poliovirus in any form.

**Current Polio Outbreak in Gaza**

The routine vaccination schedule in Gaza and the West Bank includes five dosages of OPV 1,3 and two of eIPV1,2,3. Until mid-2023, vaccination coverage was as high as 99.6% (Palestinian Ministry of Health, 2023). Nearly three months into the escalation of hostilities, an estimated 16,854 children have missed their routine vaccinations, leaving their immunity compromised at a time of significant vulnerability. Before October 7, substantial progress has been made to improve children's health and wellbeing in Palestine, with vaccination coverage of critical vaccines as high as 99 per cent. Despite continuing efforts to maintain vaccination coverage, the relentless socio-economic decline, which the conflict exacerbated, the weakness of Gaza’s already fragile healthcare infrastructure intensified by prolonged conflict and interruptions to services, all posed significant challenges, disrupting vaccinations and disease surveillance and increasing the risk of deadly but preventable diseases, such as measles and polio.24

In June 2024, Gaza faced a new polio threat following the detection of cVDPV2 in six environmental samples, followed by a verified case of cVDPV2 in a 10-month-old girl with poliomyelitis. This outbreak represents a significant public health emergency in Gaza and the wider region. The virus is genetically linked to cVDPV2 strains circulating in Egypt, reflecting the regional interconnectedness of poliovirus transmission.19

In response to this outbreak, a critical polio vaccination campaign using nOPV2 was launched on September 1, 2024, targeting more than 640,000 children under 10. This campaign was successful, with 560,000 children vaccinated between September 1–12, 2024. The next round of the vaccination campaign in Gaza began on October 14, 202426, using a scheme similar to that used in the first round, with local “tactical pauses” in fighting during the hours the campaign operates.20 Unfortunately the final phase of the campaign, aiming to vaccinate about 120,000 children across northern Gaza, has been delayed due to escalating violence and the lack of assured humanitarian pauses. We all hope the situation will improve quickly so the vaccination efforts will continue.26

The recent situation involving the spread of polio in the Middle East is an example of how local context must be considered within the current global effort to eradicate polio and highlights the importance of involving all health actors at local, regional, and global levels in implementing sustainable vaccination programmes. In the years ahead, we must also consider the legacy of the COVID-19 pandemic: misinformation and vaccine hesitancy pose serious obstacles, particularly in areas with low literacy where conspiracy theories can spread rapidly. Surveys in Gaza in 2021 and 2023 found hesitancy to receive COVID-19 vaccines was over 30%, while a qualitative study identified a range of conspiracy theories, some related to the political situation in the region. Such scepticism undermines efforts to achieve high vaccination coverage. Logistical challenges, such as maintaining a cold chain, further complicate the eradication campaign.

The Gaza situation presents some specific challenges. While not unique to Gaza, the safety of healthcare workers remains a grave concern, with targeted attacks on polio vaccination teams threatening their lives and the success of vaccination campaigns. Ensuring local ceasefires is crucial. Population movement also increases the risk of viruses spreading across borders. Weak routine vaccination programmes in high-risk environments and among populations at risk leave children vulnerable to infection while competing for health priorities and disease outbreaks strain resources and distract attention from polio eradication efforts.

Funding gaps remain a major challenge, as sustained financial support is crucial for maintaining eradication efforts yet financial flows have been compromised by political considerations by donors. Additionally, the increased detection of poliovirus in environmental samples, such as sewage, indicates ongoing transmission risks that must be addressed to achieve global eradication.

The Gaza outbreak, combined with the discovery of previously detected cVDPV2 in Israel, underscores the need for coordinated regional efforts and sustained vaccination campaigns to prevent further virus spread. Recent events, both in Israel and Gaza, have highlighted new challenges, not only for the region but also for the global eradication campaign. These events have shown the importance of CVDP and revealed the best ways to deal with this using currently available vaccines, given the differences in health system capacity and ongoing military and political conflicts.

The complex situation in the Middle East could fuel the emergence and re-emergence of infectious diseases across the region, making it essential for countries to collaborate and implement cross-border responses. Successful precedents for such cooperation exist, even in conflict areas or where frontiers are disputed. Examples in this region include the establishment of the Middle East Consortium on Infectious Disease Surveillance (MECIDS),21 as well as joint efforts during the 2009 H1N1 pandemic22 and the silent 2013 outbreak of WPV1.12 The current crisis has also encouraged WHO’s regional offices to create mechanisms to coordinate efforts when threats transcend their borders.

The current situation involving cVDPV2 in the area may require an expanded vaccination campaign with nOPV2.23 Similar initiatives, in partnership with international bodies and organisations, are urgently needed to coordinate responses to the current polio outbreak in Gaza and address other infectious disease threats that may arise from conflict in the Middle East.

**Conclusions**

Any polio outbreak demands action, but this depends on it being detected. This calls for enhanced surveillance during disasters and conflict, which often lead to the breakdown of healthcare systems, disruption of vaccination programmes, and increased population displacement. The recent cVDPV2 outbreak in Gaza underscores the fragility of global polio eradication efforts and the critical importance of maintaining high vaccination coverage, especially in conflict zones. This situation also highlights the interconnectedness of public health across borders, requiring collaboration among all actors present, including local, regional, and global partners and emphasises the need for coordinated regional responses. The successful implementation of vaccination campaigns amid conflict demonstrates the challenges and possibilities of crises. Efforts to develop and deploy more stable vaccines, such as those used in targeted nOPV2 campaigns, while ensuring comprehensive coverage with eIPV, offer hope for preventing future outbreaks. However, the ultimate success of polio eradication will depend on sustained political will, cross-border considerations to social determinants of health, coordinated health emergency responses, international cooperation, research, and innovative strategies to reach every child with life-saving vaccines and maintain enabling professional structures for monitoring and outbreak information sharing. As we navigate the complexities of the polio endgame, the lessons learned from the Gaza outbreak will be invaluable in shaping global health policies and preparedness for future infectious disease challenges.

**REFERENCES**

1. United Nations. As Israel’s bombardments intensify, ‘There is no safe place in Gaza’, humanitarian chief warns Security Council. Meetings Coverage and Press Releases. 2024 (<https://press.un.org/en/2024/sc15564.doc.htm>).
2. UN Watch. Updated report: UN silent on displaced Israelis. 2 July 2024

(https://unwatch.org/report-un-silent-on-israeli-idps/#:~:text=As%20of%20the%20end%20of,90%2C000%20Israelis%20remained%20internally%20displaced%20).

1. World Health Organization. Poliovirus detected from environmental samples in Israel and West Bank and Gaza Strip. Disease Outbreak News, September 20, 2013. (<https://www.who.int/emergencies/disease-outbreak-news/item/2013_09_20_polio-en>). Geneva: World Health Organization, 2013.
2. Tulchinsky T. Professor Natan Goldblum and the combined vaccination program in Gaza. *Am J Public Health* 2011;101:774–5
3. Slater PE, Orenstein WA, Morag A, et al.Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. *Lancet* 1990;335:1192-8
4. Flahault A, Orenstein W, Garon J, et al. Comparing Israeli and Palestinian polio vaccination policies and the challenges of silent entry of wild poliovirus in 2013-14: a ‘natural experiment.’ *Int J Public Health* 2015;60:765-6
5. Anis E, Kopel E, Singer SR, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. *Euro Surveill* 2013;18:20586
6. WHO Polio Eradication Initiative. Occupied Palestinian territory certification status:<http://www.emro.who.int/polio/certification/occupied-palestinian-territory-certification.html>
7. European Centre for Disease Prevention and Control. Epidemiological update: Polio in Israel, 14 October 2013. 2013 (https://www.ecdc.europa.eu/en/news-events/epidemiological-update-polio-israel-14-october-2013).
8. Global Polio Eradication Initiative. Poliovirus detected from environmental samples in Egypt. 2013 (https://polioeradication.org/news/poliovirus-detected-from-environmental-samples-in-egypt/).
9. Kopel E, Kaliner E, Grotto I. Lessons from a public health emergency — importation of wild poliovirus to Israel. *N Engl J Med* 2014;371:981-3
10. Tulchinsky TH, Ramlawi A, Abdeen Z, et al. Polio lessons 2013: Israel, the West Bank, and Gaza. *Lancet* 2013;382:1611-2
11. Kaliner, E., Kopel, E., Anis, E., Mendelson, E., Moran-Gilad, J., Grotto, I. “Reintroduction of Bivalent Oral Polio Vaccine (bOPV) into the National Vaccination Schedule in Israel in Response to the 2013 WPV1 Outbreak.” *Vaccine*, 2015
12. Kaliner E, Kopel E, Anis E, et al. The Israeli public health response to wild poliovirus importation. *Lancet Infect Dis* 2015;10:1236-42
13. Global Polio Eradication Initiative. Circulating Vaccine-Derived Poliovirus Type 2 – Global Update. *Disease Outbreak News*, March 2024.
14. Martin J, Burns CC, Jorba J, et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing – worldwide, March-October 2021. *Morb Mortal Wkly Rep* 2022;71:786-90
15. Precision Vaccinations. 34 countries identified in the latest polio outbreak alert. 2024 (https://www.precisionvaccinations.com/2024/06/22/34-countries-identified-latest-polio-outbreak-alert).
16. European Centre for Disease Prevention and Control. Polio cases worldwide. nd (<https://gis.ecdc.europa.eu/portal/apps/dashboards/fc1d8b9f4a8740808935600db9a96057>).
17. Global Polio Eradication Initiative. Variant type 2 poliovirus isolated from sewage samples in Gaza. 2024 (<https://polioeradication.org/news/variant-type-2-poliovirus-isolated-from-sewage-samples-in-gaza/>).
18. Global Polio Eradication Initiative. Second round of polio vaccination in the Gaza Strip aims to vaccinate over half a million children. 2024 (<https://polioeradication.org/news/second-round-of-polio-vaccination-in-the-gaza-strip-aims-to-vaccinate-over-half-a-million-children/>).
19. Leventhal A, Ramlawi A, Belbiesi A, et al. Enhanced surveillance for detection and management of infectious diseases: regional collaboration in the Middle East. *Emerg Health Threats J* 2013;6
20. Gresham L, Ramlawi A, Briski J, Richardson M, Taylor T. Trust across borders: responding to 2009 H1N1 influenza in the Middle East. *Biosecur Bioterror* 2009;7:399-404
21. Shahnoor S, Ghaffar R, Taimuri MA. Re-emergence of vaccine-derived poliovirus in Israel, US, and UK – call for promoting the use of novel oral polio vaccine. *Ann Med Surg (Lond)* 2022;82:104778
22. UNICEF: State of Palestine. Delivering life-saving vaccines to every child in the Gaza Strip. 31 December 2023 (<https://www.unicef.org/sop/stories/delivering-life-saving-vaccines-every-child-gaza-strip>).
23. The Palestinian Ministry of Health Report: Palestinian Ministry of Health, Health Annual Report Palestine 2022. (Ramallah, 2023).
24. World Health Organization. Intense bombardments, mass displacements, and lack of access in northern Gaza force the displacement of polio vaccine campaign. News Release 23 December 2024 (https://www.who.int/news/item/23-10-2024-intense-bombardments--mass-displacements-and-lack-of-access-in-northern-gaza-force-the-postponement-of-polio-vaccination-campaign).